

## Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

Joshua E. Allen<sup>1</sup>, C. Leah B. Kline<sup>2</sup>, Varun V. Prabhu<sup>1</sup>, Jessica Wagner<sup>2</sup>, Jo Ishizawa<sup>3</sup>, Neel Madhukar<sup>4</sup>, Avital Lev<sup>2</sup>, Marie Baumeister<sup>2</sup>, Lanlan Zhou<sup>2</sup>, Amriti Lulla<sup>2</sup>, Martin Stogniew<sup>1</sup>, Lee Schalop<sup>1</sup>, Cyril Benes<sup>5,6</sup>, Howard L. Kaufman<sup>7</sup>, Richard S. Pottorf<sup>8</sup>, B. Rao Nallaganchu<sup>8</sup>, Gary L. Olson<sup>8</sup>, Fahd Al-Mulla<sup>9</sup>, Madeleine Duvic<sup>3</sup>, Gen Sheng Wu<sup>10</sup>, David T. Dicker<sup>2</sup>, Mala K. Talekar<sup>11</sup>, Bora Lim<sup>3</sup>, Olivier Elemento<sup>4</sup>, Wolfgang Oster<sup>1</sup>, Joseph Bertino<sup>7</sup>, Keith Flaherty<sup>5,6</sup>, Michael L. Wang<sup>3</sup>, Gautam Borthakur<sup>3</sup>, Michael Andreeff<sup>3</sup>, Mark Stein<sup>7</sup> and Wafik S. El-Deiry<sup>2</sup>

<sup>1</sup>Oncocutics, Inc., Philadelphia, PA, USA

<sup>2</sup>Fox Chase Cancer Center, Philadelphia, PA, USA

<sup>3</sup>University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>4</sup>Weill Cornell Medicine, New York, NY, USA

<sup>5</sup>Massachusetts General Hospital, Boston, MA, USA

<sup>6</sup>Harvard Medical School, Boston, MA, USA

<sup>7</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

<sup>8</sup>Provid Pharmaceuticals, Monmouth Junction, NJ, USA

<sup>9</sup>Kuwait University Medical School, Kuwait

<sup>10</sup>Karmanos Cancer Institute, Detroit, MI, USA

<sup>11</sup>The Children's Hospital of Philadelphia, Philadelphia, PA, USA

**Published:** October 12, 2021

**Copyright:** © 2021 Allen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The COI statement has been updated. Please see the revised text below:

### CONFLICTS OF INTEREST

W.S.E-D. is a co-founder and shareholder of Oncocutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncocutics, Inc. Some of the additional authors are employees or shareholders at Oncocutics, Inc.

Original article: Oncotarget. 2016; 7:74380–74392. <https://doi.org/10.18632/oncotarget.11814>